Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

被引：246

作者：

Gapstur, S. M. ^{[1
]}

Patel, A. V. ^{[1
]}

Banks, E. ^{[2
]}

Dal Maso, L. ^{[3
]}

Talamini, R. ^{[3
]}

Chetrit, A. ^{[4
]}

Hirsh-Yechezkel, G. ^{[4
]}

Lubin, F. ^{[4
]}

Sadetzki, S. ^{[4
]}

Beral, V. ^{[5
]}

Bull, D. ^{[5
]}

Cairns, B. ^{[5
]}

Crossley, B. ^{[5
]}

Gaitskell, K. ^{[5
]}

Goodill, A. ^{[5
]}

Green, J. ^{[5
]}

Hermon, C. ^{[5
]}

Key, T. ^{[5
]}

Moser, K. ^{[5
]}

Reeves, G. ^{[5
]}

Sitas, F. ^{[6
]}

Collins, R. ^{[7
,8
]}

Peto, R. ^{[7
,8
]}

Gonzalez, C. A. ^{[9
]}

Lee, N. ^{[10
]}

Marchbanks, P. ^{[10
]}

Ory, H. W. ^{[10
]}

Peterson, H. B. ^{[10
]}

Wingo, P. A. ^{[10
]}

Martin, N. ^{[11
]}

Silpisornkosol, S. ^{[11
]}

Theetranont, C. ^{[11
]}

Boosiri, B. ^{[12
]}

Chutivongse, S. ^{[12
]}

Jimakorn, P. ^{[12
]}

Virutamasen, P. ^{[12
]}

Wongsrichanalai, C. ^{[12
]}

Goodman, M. T. ^{[13
]}

Lidegaard, O. ^{[14
]}

Kjaer, S. K. ^{[14
,15
]}

Morch, L. S. ^{[14
]}

Tjonneland, A. ^{[15
]}

Byers, T. ^{[16
]}

Rohan, T. ^{[17
]}

Mosgaard, B. ^{[18
]}

Vessey, M. ^{[19
]}

Yeates, D. ^{[19
]}

Freudenheim, J. L. ^{[20
]}

Titus, L. J. ^{[21
]}

Chang-Claude, J. ^{[22
]}

机构：

[1] Amer Canc Soc, Atlanta, GA 30329 USA

[2] Australian Natl Univ, Caberra, ACT, Australia

[3] Aviano Canc Ctr, I-33081 Aviano, Italy

[4] Gertner Inst, Tel Hashomer, Israel

[5] Canc Epidemiol Unit, Oxford, England

[6] NSW Canc Council, Woolloomooloo, NSW, Australia

[7] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England

[8] Epidemiol Studies Unit CTSU, Oxford, England

[9] Catalan Inst Oncol, Barcelona, Spain

[10] Ctr Dis Control & Prevent, Atlanta, GA USA

[11] Chiang Mai Univ, Chiang Mai, Thailand

[12] Chulalongkorn Univ, Bangkok, Thailand

[13] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[14] Copenhagen Univ Hosp, Copenhagen, Denmark

[15] Danish Canc Soc Res Ctr, Copenhagen, Denmark

[16] Colorado Sch Publ Hlth, Denver, CO USA

[17] Albert Einstein Coll Med, Bronx, NY 10467 USA

[18] Herlev Univ Hosp, Copenhagen, Denmark

[19] Dept Publ Hlth, Oxford, England

[20] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA

[21] Geisel Sch Med Dartmouth, Hanover, NH USA

[22] German Canc Res Ctr, Heidelberg, Germany

[23] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA

[24] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[25] Univ Copenhagen, Hillerod Hosp, DK-1168 Copenhagen, Denmark

[26] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England

[27] INSERM, U1018, Villejuif, France

[28] Paris South Univ, Inst Gustave Roussy, Villejuif, France

[29] Harvard Univ, Sch Med, Cambridge, MA 02138 USA

[30] Int Agcy Res Canc, F-69372 Lyon, France

[31] Univ Milan, Ist Ric Farmacol Mario Negri, I-20122 Milan, Italy

[32] Karolinska Inst, Stockholm, Sweden

[33] Maastricht Univ, NL-6200 MD Maastricht, Netherlands

[34] Mahidol Univ, Bangkok 10700, Thailand

[35] Canc Res & Prevent Inst, Florence, Italy

[36] NCI, Bethesda, MD 20892 USA

[37] MRC, Canc Epidemiol Res Grp, Natl Hlth Lab Serv, Johannesburg, South Africa

[38] Norwegian Inst Publ Hlth, Oslo, Norway

[39] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia

[40] Univ Queensland, Brisbane, Qld, Australia

[41] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[42] Royal Coll Gen Practitioners Oral Contracept Stud, London, England

[43] Curtin Univ, Sch Publ Hlth, Perth, WA 6845, Australia

[44] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA

[45] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Boston, MA 02125 USA

[46] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA

[47] Stanford Univ, Stanford, CA 94305 USA

[48] Univ Athens, Sch Med, GR-11527 Athens, Greece

[49] Univ Chile, Santiago, Chile

[50] Univ Hawaii, Honolulu, HI 96822 USA

来源：

LANCET | 2015年 / 385卷 / 9980期

基金：

英国医学研究理事会;

关键词：

THERAPY;

D O I：

10.1016/S0140-6736(14)61687-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years of use (RR 1.43, 95% CI 1.31-1.56; p<0.0001). Combining current-or-recent use (any duration, but stopped <5 years before diagnosis) resulted in an RR of 1.37 (95% CI 1.29-1.46; p<0.0001); this risk was similar in European and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but differed across the four main tumour types (heterogeneity p<0.0001), being definitely increased only for the two most common types, serous (RR 1.53, 95% CI 1.40-1.66; p<0.0001) and endometrioid (1.42, 1.20-1.67; p<0.0001). Risk declined the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was still an excess of serous or endometrioid tumours (RR 1.25, 95% CI 1.07-1.46, p=0.005). Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.

引用

页码：1835 / 1842

页数：8

共 16 条

[1]

[Anonymous], 2013, International Classification of disease for Oncology

[2]

[Anonymous], Guideline on Clinical Investigation of Medicinal Products for the Treatment of Sepsis.

[3]

Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1

[4] Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies [J].

Beral, V. ;

Bull, D. ;

Pirie, K. ;

Reeves, G. ;

Peto, R. ;

Skegg, D. ;

LaVecchia, C. ;

Magnusson, C. ;

Pike, M. C. ;

Thomas, D. ;

Hamajima, N. ;

Hirose, K. ;

Tajima, K. ;

Rohan, T. ;

Friedenreich, C. M. ;

Calle, E. E. ;

Gapstur, S. M. ;

Patel, A. V. ;

Coates, R. J. ;

Liff, J. M. ;

Talamini, R. ;

Chantarakul, N. ;

Koetsawang, S. ;

Rachawat, D. ;

Marcou, Y. ;

Kakouri, E. ;

Duffy, S. W. ;

Morabia, A. ;

Schuman, L. ;

Stewart, W. ;

Szklo, M. ;

Coogan, P. F. ;

Palmer, J. R. ;

Rosenberg, L. ;

Band, P. ;

Coldman, A. J. ;

Gallagher, R. P. ;

Hislop, T. G. ;

Yang, P. ;

Cummings, S. R. ;

Canfell, K. ;

Sitas, F. ;

Chao, P. ;

Lissowska, J. ;

Horn-Ross, P. L. ;

John, E. M. ;

Kolonel, L. M. ;

Nomura, A. M. Y. ;

Ghiasvand, R. ;

Hu, J. .

LANCET ONCOLOGY, 2012, 13 (11) :1141-1151

[5]

Beral V, 2012, LANCET ONCOL, V13, P946, DOI [10.1016/S1470-2045(12)70322-4, 10.1016/S1470-2045(12)70365-0]

[6] Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies [J].

Beral, V. ;

Hermon, C. ;

Peto, R. ;

Reeves, G. ;

Brinton, L. ;

Marchbanks, P. ;

Negri, E. ;

Ness, R. ;

Peeters, P. H. M. ;

Vessey, M. ;

Calle, E. E. ;

Gapstur, S. M. ;

Patel, A. V. ;

Dal Maso, L. ;

Talamini, R. ;

Chetrit, A. ;

Hirsh-Yechezkel, G. ;

Lubin, F. ;

Sadetzki, S. ;

Allen, N. ;

Bull, D. ;

Callaghan, K. ;

Crossley, B. ;

Gaitskell, K. ;

Goodill, A. ;

Green, J. ;

Key, T. ;

Moser, K. ;

Collins, R. ;

Doll, R. ;

Gonzalez, C. A. ;

Lee, N. ;

Ory, H. W. ;

Peterson, H. B. ;

Wingo, P. A. ;

Martin, N. ;

Pardthaisong, T. ;

Silpisornkosol, S. ;

Theetranont, C. ;

Boosiri, B. ;

Chutivongse, S. ;

Jimakorn, P. ;

Virutamasen, P. ;

Wongsrichanalai, C. ;

Tjonneland, A. ;

Titus-Ernstoff, L. ;

Byers, T. ;

Rohan, T. ;

Mosgaard, B. J. ;

Yeates, D. .

PLOS MEDICINE, 2012, 9 (04)

[7] Ovarian cancer and hormone replacement therapy in the Million Women Study [J].

Beral, Valerie ;

Bull, Diana ;

Green, Jane ;

Reeves, Gillian .

LANCET, 2007, 369 (9574) :1703-1710

[8] Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health [J].

de Villiers, T. J. ;

Pines, A. ;

Panay, N. ;

Gambacciani, M. ;

Archer, D. F. ;

Baber, R. J. ;

Davis, S. R. ;

Gompel, A. A. ;

Henderson, V. W. ;

Langer, R. ;

Lobo, R. A. ;

Plu-Bureau, G. ;

Sturdee, D. W. .

CLIMACTERIC, 2013, 16 (03) :316-337

[9]

International Agency for Research on Cancer, 2007, INT AG RES CANC MON, V91

[10] Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm [J].

Kurman, Robert J. ;

Shih, Ie-Ming .

HUMAN PATHOLOGY, 2011, 42 (07) :918-931

← 1 2 →